Celebrating Get Smart Week, October 5th-11th, 2009
This year, the Get Smart campaign hosted its first Retail Pharmacy Summit for representatives from national retail pharmacy chains, non-profit and advocacy organizations, and CDC staff. Attendees included: Rite-Aid, Kroger, Giant Eagle, Giant/Stop and Shop, Medicine Shoppe International, National Association of Chain Drug Stores, IMS Health®, Alliance for the Prudent Use of Antibiotics, as well as universities and other organizations.
Photo: CDC Federal Credit Union distributed Get Smart materials and raffled off promotional items during GSW.
The one-day meeting featured presentations on the latest science on antibiotic use and resistance, discussions on the important role pharmacists and retail pharmacies can play in educating patients, and specific and successful strategies that can enhance social responsibility and profitability through partnerships with the Get Smart campaign.
At the end of the day, attendees pledged to “Get Smart” and share information from the Retail Pharmacy Summit within their companies and explore future opportunities to partner with the campaign. Attendees were excited that CDC had provided this forum for meeting and exchanging ideas with others working on the campaign. The Get Smart campaign is currently focusing its efforts
on implementing strategies to continue to leverage partnerships – including those with retail pharmacies – and exploring ways to gain greater exposure for Get Smart messages.
The Respiratory Diseases Branch (RDB) Get Smart: Know When Antibiotics Work campaign continues to educate pharmacists, healthcare providers and the general public about the importance of appropriate antibiotic use and the growing threat of antibiotic resistance.
One of many ways the Get Smart campaign increases awareness is by working with state- based appropriate antibiotic use campaigns and with both non- and for-profit partners during the annual observance, Get Smart About Antibiotics Week (GSW).
The take home messages of GSW 2009 were that antibiotics will not cure viral infections and pharmacists can play an important role in educating patients about appropriate antibiotic use (including prescription adherence, adverse drug events and symptomatic therapy). National and local media outlets provided news coverage on the importance of appropriate antibiotic use based on a GSW press release.
The campaign’s partners distributed messages, and there was a strong internet presence, including Facebook and Twitter. NCIRD collaborated with NCHM to produce a new CDC-TV video (“Snort. Sniffle. Sneeze. No Antibiotics Please!”). A partnership with the CDC Federal Credit Union resulted in Atlanta branches distributing educational materials to their members and holding a raffle with Get Smart promotional items.
Increased incidence of Haemophilus influenzae type b, Minnesota
School-based cluster of suspected pertussis cases, Georgia
Streptococcus pneumoniae meningitis, Missouri
Legionnaires’ disease on a cruise ship, New York Increase of pertussis in La Plata County, Colorad o
July 2009 Aug 2009
Legionnaires’ disease in an apartment complex for seniors, Baltimore
Increase in invasive pneumococcal disease, Denver
Pertussis increase in two counties, Florida
Legionnaires’ disease on a cruise ship, Miami
Photo: Laura Conklin in Nairobi, Kenya - where she took her winning photo for the 2009 CDC Connects Public Health in Action Photo Contest.
Legionnaires’ disease cluster on a cruise ship, Los Angeles
Matthew Moore has been awarded a PHS Outstanding Service Medal in recognition of outstanding leadership in the prevention of pneumococcal disease.
Ryan Novak has been awarded the Commendation Medal for exemplary performance fostering international collaborations and building vaccine-preventable disease surveillance capacity in developing countries. He was also awarded the Hazardous Duty Award for efforts to reduce vaccine-preventable diseases during assignments in Pakistan collaborating with the Pakistan National Institutes of Health staff and the Pakistan Field Epidemiology and Laboratory Training Program.
The Unexplained Respiratory Disease Outbreaks Website was awarded the Unit Commendation for development and implementation of a website housing clinical, epidemiologic, laboratory and communication tools for use by public health partners to investigate respiratory outbreaks of unknown etiology.
Laura Conklin shared first place in the 2009 CDC Connects Public Health in Action Photo Contest. Her award was in the International People category for her photo of a young child in a slum outside Nairobi, Kenya. About the photo, Laura said, “The post-election violence had recently ended, but the stories of the
atrocities against members of the Kikuyu tribe that lived there were haunting as we walked among the houses on our way to the local clinic. We had to wear tall rubber boots because of the mud, and must have stood out quite a bit. At one point, a little boy came out of his house to see what we were doing. I’m just an amateur photographer, but I liked the angle of the shot because you could really get a sense of what life in Kibera is like, and the contrast with the apartment buildings in the background.”
ACIP: Updates from October 21-22, 2009 Meeting
DBD participated in the meeting during the following sessions: (1) Meningococcal Vaccines: Information & Discussion - Epidemiology of meningococcal disease in infants and young children - Jessica MacNeil; Considerations in the use of meningococcal conjugate vaccines in infants
Amanda Cohn; and (2) 13-Valent Pneumococcal Conjugate Vaccine (PCV13): Information & Discussion - PCV13: draft recommendations and
immunization schedules - Pekka Nuorti.
Hib Shortage Resolved – New Vaccine Comes to Market
On August 19, 2009 FDA licensed Hiberix, a Hib conjugate vaccine. Hiberix is licensed for use as the booster dose of the Hib vaccine series for children 15 months through 4 years of age who have previously received the primary series of Hib vaccination. With an increased vaccine supply, children with a deferred booster dose due to the shortage can now receive it. Vaccination providers are recommended to begin recall of children in need of the booster dose when feasible and monovalent Hib vaccine supply in the office is adequate.
As I was getting ready to write this note, I paused a bit to reflect on the division’s work over the last 12 months. What a busy and extremely productive year this had been! Our division staff just finished a major clinical trial for anthrax vaccine that will make this vaccine easier to administer and impact millions of military personnel. We have investigated at least ten Epi-AIDS and assisted in even more outbreaks, covering a spectrum of diseases including multiple pertussis and Legionnaires’ disease ones, but also group A streptococcal, meningococcal and pneumococcal diseases. We have attended numerous meetings and published countless papers to ensure the knowledge we gain from our work is shared and quickly communicated.
With regard to vaccine-preventable diseases in the U.S., we dealt with a Hib vaccine shortage and worked closely with ACIP to help them make policies that will improve the control of pertussis, pneumococcal, meningococcal, and Hib diseases. Globally, we worked closely with GID, WHO and our various partners internally and externally, to accelerate the introduction of Hib and pneumococcal vaccines and significantly reduce the burden of pneumonia, which remains a major killer of children in developing countries. We also helped prepare countries in the African meningitis belt for the introduction of meningococcal group A vaccine and initiated a study with PAHO to improve pertussis control in South America. In addition, our staff have helped support a variety of surveillance and evaluation studies worldwide that are crucial to strengthening the epidemiological and laboratory capacity of countries to help them better control diseases. We have continued to be actively involved in vaccine development, including some promising new ones such as pneumococcal protein vaccines.
We have contributed to the success of important health observances such as World Meningitis Day and World Pneumonia Day, which were both first time events, along with the second annual Get Smart About Antibiotics Week, some of which you’ll read about in this issue. When the H1N1 pandemic started in April, DBD staff were among
MVPDB Laboratories Step Up to H1N1 P.1 The First World Pneumonia Day P.2 Vaccine Effectiveness Analysis for MCV4 P.3 Celebrating Get Smart Week 2009 P.4
MVPDB Laboratories Step Up to the H1N1 Challenge
Photo: Members of MVPDB’s Microbial Pathogenesis and Immune Response Lab and Immunology Labs group, along with researchers from the Influenza Division and NICPHI. Not pictured are members of the Microbial Pathogenesis and Immune Response and Immunology group (VL) (Specimen Management team and the QA team).
Beginning in June, the Division of Bacterial Diseases (DBD) was requested to provide
assistance for a wide range of laboratory activities to support CDC’s response to the emerging H1N1 influenza pandemic. Many laboratory and epidemiology staff willingly gave their time and expertise to assist in this high profile activity – one of CDC’s highest current priorities.
Fresh from their successful contributions to the CDC Anthrax Vaccine Research Program (AVRP), the DBD Microbial Pathogenesis and Immune Response (MPIR) Laboratory
one part of the Meningitis and Vaccine Preventable
Diseases Branch (MVPDB) Vaccinology Laboratories group
joined the H1N1 response effort.
The Influenza Division’s Immunology and Pathogenesis Branch (IPB), Pandemic Preparedness Team (PP Team) faced the enormous task of testing and analyzing thousands of pandemic H1N1 serum samples. The MPIR Lab, fuelled by this exciting challenge, integrated forces with the PP Team, and provided highly skilled critical staff, equipment, expertise and laboratory surge capacity to handle both the immediate needs, and the anticipated surge of specimen testing.
The MPIR Lab collaborated directly with the PP Team to attack three high priority goals: to collate, organize and prepare for testing the backlog of serum samples received at CDC; to use existing expertise with STARLIMS
a laboratory information management system – for
sample management and data storage; and to establish a
the first to assist in the response and have continued providing support. As part of the Recovery Act, huge efforts were invested by our staff to initiate various studies, contributing to the nation’s economic recovery. I can go on and on, but these are just some of DBD’s recent highlights. As 2009 draws to an end, we should all be very proud of what we have accomplished this yea , and recognize that our work has not only increased the public health knowledge, but has also made the U.S. and the world better prepared to prevent and control diseases and overall healthier. I wish you all happy and restful holidays!
sustainable capacity for high throughput, high efficiency testing and results reporting. The MPIR Lab seized this opportunity to assist and integrate to the fullest extent possible – and for the highest public health impact – their key skills and expertise. A highly effective collaboration with the PP Team emerged.
The MPIR Lab capabilities were developed for the CDC AVRP and honed in the evaluation of anthrax vaccines, therapeutics and in clinical diagnostics. The capabilities derive from a cadre of highly trained laboratory team members with subject matter expertise in five key areas: high volume/high throughput specimen handling, quality controlled high volume serological testing, large volume data analysis and reporting, relational database management (STARLIMS), and an overarching quality management system (QMS). While it took the MPIR Lab several years to design, build and implement these key success factors for anthrax, it has taken only 4 months in collaboration with the PP Team to redirect, develop and implement most aspects of this sustainable system to support the H1N1 surge activity.
The MPIR Lab’s specimen management team, NCIRD volunteers and new IPB recruits provided the capacity and discipline to organize and handle large numbers of specimens quickly and accurately. The MPIR Lab data analysis team created standardized, high throughput SAS® based macro programs for rapid collation, analysis, interpretation and reporting of assay results. The MPIR Lab quality assurance (QA) team continues to work closely with the Influenza Division’s QA Unit to develop a QMS that not only is customized for the PP Team but also aligns with the NCIRD vision of a center-wide QMS. Two experienced laboratorians from the MPIR Lab and one from the MVPDB Immunology Labs received assay- specific training and joined forces with the PP Team to carry out the enormous task of running the assays to detect anti-H1N1 antibodies.
In a ‘mentoring’ capacity for STARLIMS implementation, the MPIR Lab assisted the PP Team by providing the STARLIMS MPIR unit as an immediate and efficient tool to accession all H1N1 serology samples. The MPIR Lab and PP Teams are working with the STARLIMS implementation
(Continued on page 3...)